Literature DB >> 31930996

Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Morgan H James1, Gary Aston-Jones2.   

Abstract

Entities:  

Keywords:  Alcohol; Anxiety; Cocaine; Medications; Opioids; Stress; Suvorexant; Therapeutics

Mesh：

Substances：

Year:  2020        PMID： 31930996      PMCID： PMC7181304          DOI： 10.1016/j.brainres.2020.146665

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


× No keyword cloud information.
  46 in total

Review 1.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 2.  Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

Authors:  R T Owen
Journal:  Drugs Today (Barc)       Date:  2016-01       Impact factor: 2.245

3.  Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1).

Authors:  Coleman B Calva; Habiba Fayyaz; Jim R Fadel
Journal:  J Neurochem       Date:  2018-01-12       Impact factor: 5.372

4.  Lateral hypothalamic orexin glucose-inhibited neurons may regulate reward-based feeding by modulating glutamate transmission in the ventral tegmental area.

Authors:  Suraj B Teegala; Zhenyu Sheng; Miloni S Dalal; Pamela R Hirschberg; Kevin D Beck; Vanessa H Routh
Journal:  Brain Res       Date:  2018-05-19       Impact factor: 3.252

5.  Activation of medial hypothalamic orexin neurons during a Go/No-Go task.

Authors:  Linnea R Freeman; Gary Aston-Jones
Journal:  Brain Res       Date:  2018-09-01       Impact factor: 3.252

Review 6.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

7.  Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats.

Authors:  Robyn Mary Brown; Shaun Yon-Seng Khoo; Andrew John Lawrence
Journal:  Int J Neuropsychopharmacol       Date:  2013-04-22       Impact factor: 5.176

8.  Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan
Journal:  Arch Gen Psychiatry       Date:  2004-08

9.  A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior.

Authors:  Ainhoa Plaza-Zabala; África Flores; Elena Martín-García; Rocío Saravia; Rafael Maldonado; Fernando Berrendero
Journal:  Neuropsychopharmacology       Date:  2013-03-21       Impact factor: 7.853

10.  The role of orexin-1 receptor signaling in demand for the opioid fentanyl.

Authors:  Jennifer E Fragale; Caroline B Pantazis; Morgan H James; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2019-05-21       Impact factor: 7.853
View more
  6 in total

1.  Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial.

Authors:  Thomas C Neylan; Anne Richards; Thomas J Metzler; Leslie M Ruoff; Jonathan Varbel; Aoife O'Donovan; Melinda Sivasubramanian; Terri Motraghi; Jennifer Hlavin; Steven L Batki; Sabra S Inslicht; Kristin Samuelson; Stephen R Morairty; Thomas S Kilduff
Journal:  Sleep       Date:  2020-10-13       Impact factor: 5.849

Review 2.  New directions in modelling dysregulated reward seeking for food and drugs.

Authors:  Robyn M Brown; Christopher V Dayas; Morgan H James; Rachel J Smith
Journal:  Neurosci Biobehav Rev       Date:  2021-11-02       Impact factor: 8.989

Review 3.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

Review 4.  Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link.

Authors:  Jacqueline B Mehr; Deborah Mitchison; Hannah E Bowrey; Morgan H James
Journal:  Neuropsychopharmacology       Date:  2021-06-18       Impact factor: 7.853

5.  The sensation seeking trait confers a dormant susceptibility to addiction that is revealed by intermittent cocaine self-administration in rats.

Authors:  Shayna L O'Connor; Gary Aston-Jones; Morgan H James
Journal:  Neuropharmacology       Date:  2021-04-20       Impact factor: 5.273

6.  Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking.

Authors:  Giuseppe Giannotti; Francesca Mottarlini; Jasper A Heinsbroek; Mitchel R Mandel; Morgan H James; Jamie Peters
Journal:  Transl Psychiatry       Date:  2022-10-04       Impact factor: 7.989
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.